Today’s Stock On Watch: It Seems Bellicum Pharmaceuticals Inc Will Go Up. Have Another Big Increase

Today's Stock On Watch: It Seems Bellicum Pharmaceuticals Inc Will Go Up. Have Another Big Increase

The stock of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) is a huge mover today! About 229,590 shares traded hands. Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) has risen 70.76% since April 28, 2016 and is uptrending. It has outperformed by 64.84% the S&P500.
The move comes after 5 months positive chart setup for the $454.30M company. It was reported on Dec, 1 by Barchart.com. We have $18.98 PT which if reached, will make NASDAQ:BLCM worth $27.26M more.

Analysts await Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) to report earnings on March, 13. They expect $-0.61 EPS, up 3.17% or $0.02 from last year’s $-0.63 per share. After $-0.66 actual EPS reported by Bellicum Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -7.58% EPS growth.

Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) Ratings Coverage

Out of 8 analysts covering Bellicum Pharmaceuticals Inc (NASDAQ:BLCM), 6 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 75% are positive. Bellicum Pharmaceuticals Inc has been the topic of 11 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The rating was initiated by SunTrust on Friday, June 3 with “Buy”. Citigroup maintained Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) on Tuesday, August 9 with “Neutral” rating. The firm has “Buy” rating by Cantor Fitzgerald given on Wednesday, November 2. Citigroup initiated the stock with “Neutral” rating in Thursday, February 25 report. The stock has “Buy” rating given by Citigroup on Friday, July 24. The firm has “Buy” rating given on Friday, June 3 by Suntrust Robinson. The stock of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) earned “Hold” rating by Zacks on Wednesday, August 19. The firm earned “Sell” rating on Monday, September 21 by Zacks. On Tuesday, August 9 the stock rating was maintained by Jefferies with “Buy”. The rating was upgraded by Guggenheim to “Buy” on Friday, September 11.

According to Zacks Investment Research, “Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company’s lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials. It is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Bellicum Pharmaceuticals, Inc. is based in Houston, Texas.”

More notable recent Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) news were published by: Marketwatch.com which released: “Bellicum Pharmaceuticals upgraded to buy from neutral at Citigroup” on December 18, 2014, also Fool.com with their article: “Better Buy: Bellicum Pharmaceuticals, Inc. vs. Juno Therapeutics, Inc.” published on June 26, 2016, Fool.com published: “Better Buy: Agenus Inc. vs. Bellicum Pharmaceuticals Inc.” on October 18, 2016. More interesting news about Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) were released by: Fool.com and their article: “Better Buy: Bellicum Pharmaceuticals, Inc. vs. Celldex Therapeutics” published on August 03, 2016 as well as Quotes.Wsj.com‘s news article titled: “News Bellicum Pharmaceuticals Inc.BLCM” with publication date: December 13, 2014.

BLCM Company Profile

Bellicum Pharmaceuticals, Inc., incorporated on July 14, 2004, is a clinical-stage biopharmaceutical company. The Firm is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Firm uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Firm is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company’s product candidates include BPX-501, BPX-401, BPX-601 and BPX-701. The Company’s CID technologies include CaspaCIDe, CIDeCAR and GoCAR-T.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment